Generic Drug User Fee Rates for Fiscal Year 2027
Published Date: 7/30/2026
Notice
Summary
The Federal Food, Drug, and Cosmetic Act (FD&C Act or statute), as amended by the Generic Drug User Fee Amendments of 2022 (GDUFA III), authorizes the Food and Drug Administration (FDA, Agency, or we) to assess and collect fees for abbreviated new drug applications (ANDAs); drug master files (DMFs); generic drug active pharmaceutical ingredient (API) facilities, finished dosage form (FDF) facilities, and contract manufacturing organization (CMO) facilities; and generic drug applicant program user fees. In this document, FDA is announcing fiscal year (FY) 2027 rates for GDUFA III fees.
Analyzed Economic Effects
6 provisions identified: 0 benefits, 6 costs, 0 mixed.
FY2027 GDUFA Fee Schedule Set
The FDA set the FY2027 Generic Drug User Fee rates that take effect October 1, 2026 through September 30, 2027. Key line items include an ANDA fee of $375,684, a DMF fee of $109,899, domestic API facility fee of $39,680, domestic FDF facility fee of $230,033, and a large applicant program fee of $1,927,291.
ANDA Filing Fee Requirement
Each applicant that submits an Abbreviated New Drug Application (ANDA) on or after October 1, 2026 must pay a filing fee of $375,684 due on the ANDA submission date. If an ANDA is refused-to-receive (RTR) for reasons other than failure to pay fees or is withdrawn prior to receipt, 75 percent of the ANDA fee is refundable under the rule.
Facility Annual Fees and $15K Foreign Differential
Owners of facilities identified in at least one approved generic drug submission owe annual facility fees in FY2027: domestic API $39,680 and foreign API $54,680; domestic FDF $230,033 and foreign FDF $245,033; domestic CMO $55,208 and foreign CMO $70,208. The foreign fee is $15,000 higher than the corresponding domestic fee.
Tiered Applicant Program Fees by ANDA Count
Generic drug applicant program fees for FY2027 are tiered based on approved ANDA ownership as of October 1, 2026: small (1–5 approved ANDAs) pay $192,729, medium (6–19) pay $770,916, and large (20 or more) pay $1,927,291. FDA estimated there will be 196 small-tier, 67 medium-tier, and 78 large-tier applicants for FY2027.
DMF One-Time Fee for Referenced Files
Owners of Type II API Drug Master Files (DMFs) that are first referenced in an ANDA or that request the initial completeness assessment on or after October 1, 2026 owe a one-time DMF fee of $109,899. FDA estimated 303 fee-paying DMFs for FY2027 and uses that denominator to set the $109,899 fee.
Operating Reserve Reduced FY2027 Revenue
FDA applied an operating reserve adjustment of -$36,160,352 because estimated FY2026 carryover equaled 14.68 weeks of operations, exceeding the 12-week threshold. After inflation and adjustments, the total FY2027 revenue amount used to set fees is $665,986,000 (rounded).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-15345, Food Safety Modernization Act Voluntary Qualified Importer Program User Fee Rate for Fiscal Year 2027
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 annual fee rate for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) that is authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA). This fee is effective on August 1, 2026, and will remain in effect through September 30, 2027.
2026-15336, Food Safety Modernization Act Domestic and Foreign Facility Reinspection, Recall, and Importer Reinspection Fee Rates for Fiscal Year 2027
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 fee rates for certain domestic and foreign facility reinspections, failures to comply with a recall order, and importer reinspections that are authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA).
2026-15346, Biosimilar User Fee Rates for Fiscal Year 2027
Starting October 1, 2026, companies making biosimilar drugs will pay updated fees to the FDA for developing and getting approval for their products. These fees cover new drug development, application reviews, and yearly program costs. This helps the FDA keep biosimilar drug reviews speedy and fair while supporting innovation.
2026-15335, Medical Device User Fee Rates for Fiscal Year 2027
The Food and Drug Administration (FDA, Agency, or we) is announcing the fee rates and payment procedures for medical device user fees for fiscal year (FY) 2027. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Medical Device User Fee Amendments of 2022 (MDUFA V), authorizes FDA to collect user fees for certain medical device submissions and annual fees both for certain periodic reports and for establishments subject to registration. This notice establishes the fee rates for FY 2027, which apply from October 1, 2026, through September 30, 2027, and provides information on how the fees for FY 2027 were determined, the payment procedures you should follow, and how you may qualify for reduced small business fees.
Previous / Next Documents
Previous: 2026-15342, Outsourcing Facility Fee Rates for Fiscal Year 2027
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 rates for the establishment and reinspection fees related to entities that compound human drugs and elect to register as outsourcing facilities under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FD&C Act authorizes FDA to assess and collect an annual establishment fee from outsourcing facilities, as well as a reinspection fee for each reinspection of an outsourcing facility. This document establishes the FY 2027 rates for the small business establishment fee ($7,142), the non-small business establishment fee ($22,074), and the reinspection fee ($21,427) for outsourcing facilities; provides information on how the fees for FY 2027 were determined; and describes the payment procedures outsourcing facilities should follow.
Next: 2026-15344, Over-the-Counter Monograph Drug User Fee Rates for Fiscal Year 2027
The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Over-the-Counter Monograph Drug User Fee Amendments (herein referred to as "OMUFA II"), authorizes the Food and Drug Administration (FDA, the Agency, or we) to assess and collect user fees from qualifying manufacturers of over-the-counter (OTC) monograph drugs and submitters of OTC monograph order requests (OMORs) for fiscal years 2026 through 2030. This notice publishes the OMUFA fee rates for fiscal year (FY) 2027.